-
DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix
•
South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to further develop the anti-cancer vaccine. OVM is anticipated to initiate a Phase Ib study for the vaccine in the UK in the near future, while DxVx will launch a study in Asia, encompassing South Korea…
-
KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities
•
KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local firm Truking Technology Ltd (SHE: 300358) concerning KingWise’s facilities for gynecological tumor gene therapy products. Truking will offer KingWise a comprehensive end-to-end (EPC) solution for biopharmaceutical front-end processes, including factory design, purification engineering, water distribution…
-
Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China
•
Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication approval from China’s National Medical Products Administration (NMPA) for its drug Takecab (vonoprazan) to eradicate Helicobacter pylori (HP) when combined with appropriate antibiotics. The vonoprazan-based quadruple regimen, which includes bismuth, is the first of its…
-
Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China
•
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its Category 1 product, GST-HG171/ritonavir, an oral COVID-19 therapy, has received conditional marketing approval in China. GST-HG171 is a 3CL protease (3CLpro) inhibitor, characterized as having broad-spectrum anti-COVID-19 activity. 3CL protease is an essential protease for…
-
Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its RET inhibitor A400/EP0031 in the treatment…
-
Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that it has received ethical approval from Beijing Hospital to conduct a Phase III clinical study. The study will assess the diagnostic efficacy of a radionuclide candidate, intended for use with positron emission tomography (PET) imaging,…
-
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…
-
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial
•
Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a Phase III clinical study for its pipeline candidate KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA). The multi-center, open-label, long-term safety Phase III clinical trial conducted in China…
